You just read:

Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics

News provided by

Eli Lilly and Company , Incyte Corporation

31 Mar, 2016, 07:00 ET